Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Mortality hazard ratios for women diagnosed with breast cancer between 2005 and 2011 and receiving HCAI care only and some HCAI care compared with other London women

From: Comparing the case mix and survival of women receiving breast cancer care from one private provider with other London women with breast cancer: pilot data exchange and analyses

  Unadjusted Adjusted for age Adjusted for age and deprivation Adjusted for age, deprivation, and year of diagnosis Adjusted for age, deprivation, year of diagnosis, and stage Adjusted for age, deprivation, year of diagnosis, stage, and treatment
  HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Other London women 1.00 1.00 1.00 1.00 1.00 1.00
HCAI care only 0.48 (0.32, 0.74) 0.66 (0.43, 1.02) 0.70 (0.46, 1.08) 0.70 (0.45, 1.07) 0.72 (0.47, 1.10) 0.79 (0.51, 1.21)
Some HCAI care 0.24 (0.14, 0.41) 0.32 (0.19, 0.54) 0.34 (0.20, 0.58) 0.35 (0.21, 0.59) 0.40 (0.24, 0.67) 0.48 (0.28, 0.80)
χ 2-test (2 d.f.) 39.35 21.69 18.40 18.30 14.03 8.83
p-heterogeneity <0.0001 <0.0001 <0.0001 0.0001 0.0009 0.0121
Age group
 <40   1.00 1.00 1.00 1.00 1.00
 40-44   0.85 (0.72, 1.01) 0.86 (0.73, 1.02) 0.86 (0.73, 1.02) 0.88 (0.74, 1.03) 0.96 (0.81, 1.13)
 45-49   0.77 (0.65, 0.89) 0.78 (0.67, 0.91) 0.78 (0.67, 0.92) 0.81 (0.70, 0.95) 0.89 (0.76, 1.04)
 50-54   0.65 (0.56, 0.77) 0.67 (0.57, 0.78) 0.67 (0.57, 0.78) 0.78 (0.66, 0.91) 0.86 (0.74, 1.01)
 55-59   0.83 (0.72, 0.97) 0.86 (0.74, 1.00) 0.85 (0.74, 0.99) 0.97 (0.84, 1.13) 1.11 (0.95, 1.29)
 60-64   0.85 (0.73, 0.99) 0.88 (0.76, 1.02) 0.88 (0.76, 1.02) 1.06 (0.91, 1.23) 1.27 (1.10, 1.48)
 65-69   1.05 (0.91, 1.21) 1.08 (0.93, 1.25) 1.08 (0.93, 1.24) 1.30 (1.12, 1.50) 1.65 (1.42, 1.91)
 70-74   2.01 (1.74, 2.30) 2.07 (1.80, 2.39) 2.07 (1.80, 2.38) 2.24 (1.95, 2.58) 2.83 (2.45, 3.27)
 75-79   2.85 (2.49, 3.26) 2.94 (2.57, 3.36) 2.94 (2.57, 3.36) 3.08 (2.69, 3.53) 3.91 (3.40, 4.50)
 80+   6.19 (5.48, 6.99) 6.41 (5.67, 7.24) 6.42 (5.69, 7.26) 6.10 (5.40, 6.89) 6.87 (6.03, 7.82)
χ 2-test (1 d.f.)   2,755.90 2,804.15 2,804.01 2,540.64 2,052.19
p-trend   <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Socioeconomic deprivation quintile
 1 = Affluent    1.00 1.00 1.00 1.00
 2    0.97 (0.88, 1.07) 0.96 (0.87, 1.06) 0.97 (0.87, 1.07) 0.97 (0.87, 1.07)
 3    1.06 (0.96, 1.16) 1.05 (0.96, 1.15) 1.04 (0.95, 1.15) 1.04 (0.95, 1.14)
 4    1.18 (1.08, 1.29) 1.18 (1.08, 1.29) 1.19 (1.09, 1.30) 1.16 (1.07, 1.27)
 5 = Deprived    1.37 (1.26, 1.49) 1.36 (1.25, 1.48) 1.27 (1.17, 1.38) 1.22 (1.12, 1.33)
χ 2-test (1 d.f.)    92.81 92.14 61.05 44.50
p-trend    <0.0001 <0.0001 <0.0001 <0.0001
Year of diagnosis
 2005     1.00 1.00 1.00
 2006     0.99 (0.91, 1.07) 1.08 (0.99, 1.17) 1.08 (1.00, 1.17)
 2007     1.00 (0.92, 1.09) 1.10 (1.02, 1.20) 1.07 (0.98, 1.16)
 2008     0.98 (0.89, 1.06) 1.11 (1.01, 1.21) 1.02 (0.93, 1.11)
 2009     0.87 (0.79, 0.96) 0.93 (0.85, 1.03) 0.87 (0.80, 0.96)
 2010     0.81 (0.73, 0.90) 0.82 (0.74, 0.91) 0.84 (0.76, 0.93)
 2011     0.74 (0.65, 0.84) 0.81 (0.72, 0.92) 0.83 (0.73, 0.94)
χ 2-test (1 d.f.)     33.22 22.52 27.02
p-trend     <0.0001 <0.0001 <0.0001
Stage of disease
 1      1.00 1.00
 2      1.02 (0.94, 1.11) 1.10 (1.01, 1.19)
 3      2.28 (2.07, 2.51) 2.27 (2.06, 2.51)
 4      6.37 (5.89, 6.90) 4.90 (4.52, 5.31)
 Not known      2.67 (2.47, 2.88) 1.82 (1.68, 1.96)
χ 2-test (1 d.f.)      2,924.02 1,630.20
Excl. NK p-trend      <0.0001 <0.0001
Radiotherapy
 No       1.00
 Yes       0.82 (0.77, 0.89)
χ 2-test (1 d.f.)       28.19
p-heterogeneity       <0.0001
Chemotherapy
 No       1.00
 Yes       1.29 (1.20, 1.38)
χ 2-test (1 d.f.)       50.87
p-heterogeneity       <0.0001
Cancer surgery
 No       1.00
 Yes       0.40 (0.37, 0.42)
χ 2-test (1 d.f.)       962.80
p-heterogeneity       <0.0001
Hormone therapy
 No       1.00
 Yes       0.80 (0.75, 0.85)
χ 2-test (1 d.f.)       58.07
p-heterogeneity       <0.0001
Back to article page